The $12 million PRIME study will involve 2,000 veterans with major depressive disorder and 250 healthcare providers across 21 VA medical centers.
The company, which first signed on to provide services to the VA's Million Veteran Program in 2013, will provide the department with 34,000 more genomes.
The test analyzes clinically relevant genetic variants for 14 genes related to certain pain and mental health medication responses to help guide clinicians' prescribing decisions.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The VA has been steadily increasing its capacity to whole-genome sequence enrollees, and may now sequence as many as 30,000 individuals over the next two years.
The deal replaces an existing cancer testing contract to include PGDx's CancerSelect 125 test for pan-cancer tumor profiling.
VA patients will now have access to Polymedco's colorectal cancer screening products, including the Epigenomics Epi proColon.
The contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans within the VA health system.
The company will apply artificial intelligence to a large clinical and genomic dataset from VA records in order to support personalized clinical decision making.
Researchers describe a way to share data while keeping it secure, Agence France Presse reports.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.
A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.